Diabetes: adapt management to account for cardiovascular disease risk
Professor Peter J Grant and Professor Francesco Cosentino highlight the key recommendations from the 2019 ESC/EASD guideline on diabetes, pre-diabetes, and CVD
Key learning points: diabetes in older people with frailty
Professor Alan Sinclair explains how care should be personalised and targets adapted for older people with diabetes, including an assessment of frailty
Type 2 diabetes: the role of the practice pharmacist
Muhammad Siddiqur Rahman highlights the integral role of practice-based pharmacists in managing type 2 diabetes
Co-morbidities in type 2 diabetes
Dr Kevin Fernando describes eight common co-morbidities in patients with type 2 diabetes and how the co-existing conditions should be managed
Type 2 diabetes: what are the benefits and risks of glucose-lowering agents?
Dr Kevin Fernando explains how SIGN 154 offers evidence-based guidance on glucose control therapies for people with type 2 diabetes
Test and reflect
Our multiple-choice questions (MCQs) are designed to help you test your knowledge and reflect on your learning after reading an article.
Educational resources
Trajenta® (linagliptin) 5 mg film-coated tablets
Information intended for healthcare professionals only.
Guideline for the managed introduction of biosimilar basal insulin
Guidelines identified a need for clinical guidance in a specific area and approached Mylan for an educational grant to support the development of a working party guideline. This working party guideline was developed by Guidelines, and the Chair and members of the group were chosen by and convened by ...
Formulary decision guide: Ozempic®▼ (semaglutide)
Information intended for healthcare professionals only. This formulary decision guide was developed from content supplied by Novo Nordisk in a format developed by Guidelines in Practice. It has been reviewed by Novo Nordisk, who commissioned the development of the formulary decision guide.
Management of hyperglycaemia in type 2 diabetes, 2018: ADA/EASD consensus report
Watch this short animation, commissioned by Napp Pharmaceuticals Limited, to find out about the third joint consensus report on the management of hyperglycaemia in type 2 diabetes by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Semglee® ▼ (insulin glargine biosimilar)
This formulary decision guide was developed from content provided by Mylan Ltd in a format developed by Guidelines in Practice.
Related Guidelines summaries
-
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
-
NICE type 2 diabetes guideline
This summary provides recommendations on blood glucose targets, patient education, and includes a useful algorithm on blood glucose management
-
Type 2 diabetes treatment pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
-
Type 2 diabetes: frailty in older people
Summary covers glycaemic targets for older people, priorities for improving high-quality diabetes care, and a useful frailty assessment pathway.
-
NICE pancreatitis guideline
Summary of NICE guidance on pancreatitis covers managing complications, nutrition support, and referral for specialist treatment.